Clara Mayo‐de‐las‐Casas

Author

Also Known As

C. Mayo-De-Las-Casas, C. Mayo-de-las-Casas, Clara Mayo-De-Las-Casas, Clara Mayo-de-Las-Casas, Clara Mayo-de-las-Casas, Clara Mayo‐de‐Las‐Casas, Clara Mayo‐de‐las‐Casas

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Instituto Oncológico Dr. Rosell Institut Català d'Oncologia Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Hospital Universitario Dexeus University of Naples Federico II

About

Clara Mayo‐de‐las‐Casas is an author at Instituto Oncológico Dr. Rosell specializing in pathology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	369
2	Engineering	1	1	131
3	Biomedical Engineering	1	1	131
4	Genetic Medicine	1	1	17
5	Genomic Medicine	1	1	17

Clara Mayo‐de‐las‐Casas

Publications

949

Citations

H-Index

Page 1

	Year	Citations
Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Amaya Gascó, Clinical Cancer Research	2014	193
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations Ignasi García-Olivé, Eduard Monsó, Felipe Andreo, European Respiratory Journal	2009	132
Real-time liquid biopsies become a reality in cancer treatment. Niki Karachaliou, Clara Mayo‐de‐las‐Casas, Miguel Ángel Molina‐Vila, PubMed Tumor BiologyTissue BiopsyOncologyEngineeringCancer Detection	2015	131
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions Clara Mayo‐de‐las‐Casas, Núria Jordana‐Ariza, Mónica Garzón‐Ibáñez, Annals of Oncology OncologyMedicineLarge ScalePathologyAdvanced Nsclc Patients	2017	98
Consistency and reproducibility of next‐generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens Umberto Malapelle, Clara Mayo‐de‐las‐Casas, Miguel Ángel Molina‐Vila, Cancer Cytopathology	2017	89
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions Sergi Villatoro, Clara Mayo‐de‐las‐Casas, Núria Jordana‐Ariza, Molecular Oncology	2019	83
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors María González‐Cao, Clara Mayo‐de‐las‐Casas, Miguel Ángel Molina‐Vila, Melanoma Research ImmunologyPathologyNucleic Acid BiomarkersTumor BiologyOncology	2015	78
Consistency and reproducibility of next‐generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens Pasquale Pisapia, Umberto Malapelle, Gianluca Roma, Cancer Cytopathology	2019	49
Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof‐of‐concept study Clara Mayo‐de‐las‐Casas, Ana Velasco, Alejandro Martínez‐Bueno, International Journal of Cancer Proof‐of‐concept StudyPeritoneal LavagesEarly Stage EcTumoral PathologySomatic Variant	2020	24
Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report Roxana Reyes, Clara Mayo‐de‐las‐Casas, Cristina Teixidó, Clinical Lung Cancer Tumor BiologyBraf/mek InhibitionMedicinePathologyBronchial Neoplasm	2019	21

Page 1